The bill aims to reduce overdose harms and speed enforcement by permanently scheduling specific nitazene opioids and accelerating rulemaking, but does so at the cost of restricting research, exposing some parties to retroactive liability and immediate compliance burdens, and reducing procedural safeguards for affected stakeholders.
People at risk of overdose (including urban and rural communities) will have reduced access to highly potent nitazene opioids, lowering overdose and poisoning risks.
Federal agencies must issue implementing rules within one year and may make interim final rules immediately effective while taking public comment, giving faster regulatory clarity, earlier enforcement ability, and some public participation.
Law enforcement will have clearer legal authority to prosecute possession, distribution, and manufacturing of the specified nitazene opioids.
Scientists and clinicians face much stricter barriers to study or use these compounds because Schedule I status triggers heavy registration, security, and paperwork requirements.
Patients with chronic conditions and the broader healthcare system may see delays in development and clinical research toward potentially beneficial therapies because of increased regulatory burden on research.
Individuals and businesses that handled substances previously under temporary scheduling may face retroactive criminal or civil liability and new compliance costs effective as of enactment.
Based on analysis of 6 sections of legislative text.
Adds 2-benzylbenzimidazole (nitazene) opioids and named examples to Schedule I, makes temporary emergency schedules permanent, and requires AG rulemaking within one year.
Introduced March 18, 2026 by Robert E. Latta · Last progress March 18, 2026
Adds a class of synthetic opioids called 2-benzylbenzimidazole opioids (commonly referred to as certain "nitazenes") to Schedule I of the Controlled Substances Act, covering any material, compound, mixture, or preparation containing any quantity of such substances or their salts/isomers, and names several specific nitazene compounds. The Attorney General is authorized to publish a list of covered substances, any substances already temporarily scheduled under existing emergency authority are made permanently Schedule I as of enactment, and the Attorney General must issue implementing rules within one year (interim final rules allowed with later opportunity for comment).